Bristol Myers Squibb Company (NYSE:BMY) Shares Sold by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC reduced its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,730 shares of the biopharmaceutical company's stock after selling 11,502 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in Bristol Myers Squibb were worth $1,752,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Bristol Myers Squibb by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock valued at $10,743,262,000 after purchasing an additional 1,373,209 shares during the last quarter. Capital International Investors increased its stake in Bristol Myers Squibb by 7.5% in the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after purchasing an additional 3,218,865 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Bristol Myers Squibb by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock worth $2,505,967,000 after acquiring an additional 1,187,231 shares during the last quarter. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $1,989,525,000. Finally, Ameriprise Financial Inc. grew its position in shares of Bristol Myers Squibb by 59.9% during the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock worth $1,814,341,000 after acquiring an additional 12,011,983 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Samit Hirawat purchased 4,250 shares of the business's stock in a transaction dated Friday, April 25th. The stock was acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president directly owned 83,513 shares of the company's stock, valued at $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.07% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BMY. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. UBS Group decreased their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Jefferies Financial Group decreased their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price target on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock traded up $0.64 during midday trading on Wednesday, reaching $47.68. The company's stock had a trading volume of 11,733,095 shares, compared to its average volume of 12,856,229. The firm has a market capitalization of $97.03 billion, a PE ratio of 17.86, a P/E/G ratio of 1.38 and a beta of 0.36. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. Bristol Myers Squibb Company has a fifty-two week low of $39.71 and a fifty-two week high of $63.33. The stock's 50 day simple moving average is $47.65 and its 200 day simple moving average is $53.46.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business's revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($4.40) EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.20%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.